• Suha Abu Khalaf, Dima Dandachi, Bruno P Granwehr, and Maria C Rodriguez-Barradas.
• Department of Medicine, Division of Infectious Diseases, University of Missouri System, Columbia, Missouri, USA abukhalafs@health.missouri.edu.
• J. Investig. Med. 2022 Apr 1; 70 (4): 883-891.

AbstractThe availability of antiretroviral therapy (ART) has increased the life expectancy of people with HIV (PWH) and reduced the incidence of AIDS-associated malignancies, yet PWH have a significantly increased incidence of malignancy and less favorable outcomes of cancer treatment compared with the general population.Immunotherapy has revolutionized cancer therapy, becoming the standard of care for various malignancy treatments. However, PWH are an underserved population with limited access to clinical trials and cancer treatment.This review of the available evidence on different classes of cancer immunotherapy in PWH is mostly based on case reports, case series, but few prospective studies and clinical trials due to the exclusion of PWH from most oncologic clinical trials. The results of the available evidence support the safety of immunotherapy in PWH. Immunotherapy has similar effectiveness in PWH, an acceptable toxicity profile, and has no clinically significant impact on HIV viral load and CD4-T cell count. In addition, there is no reported change in the incidence of opportunistic infections and other complications for PWH with well-controlled viremia.This review aims to briefly summarize the current state of immunotherapy in cancer, guide clinicians in the management of immunotherapy in cancer PWH, and encourage the inclusion of PWH in clinical trials of cancer immunotherapy.© American Federation for Medical Research 2022. No commercial re-use. See rights and permissions. Published by BMJ.

15 keywords...

hide…